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The replication-deficient orthopoxvirus modified vaccinia virus Ankara (MVA) is a promising vaccine 
vector against various pathogens and has an excellent safety record. However, pre-existing vector-
specific immunity is frequently suggested to be a drawback of MVA-based vaccines. To address 
this issue, mice were vaccinated with MVA-based influenza vaccines in the presence or absence of 
orthopoxvirus-specific immunity. Importantly, protective efficacy of an MVA-based influenza vaccine 
against a homologous challenge was not impaired in the presence of orthopoxvirus-specific pre-existing 
immunity. Nonetheless, orthopoxvirus-specific pre-existing immunity reduced the induction of antigen-
specific antibodies under specific conditions and completely prevented induction of antigen-specific T 
cell responses by rMVA-based vaccination. Notably, antibodies induced by vaccinia virus vaccination, 
both in mice and humans, were not capable of neutralizing MVA. Thus, when using rMVA-based 
vaccines it is important to consider the main correlate of protection induced by the vaccine, the vaccine 
dose and the orthopoxvirus immune status of vaccine recipients.
Recombinant viral vectors are under development as novel vaccine candidates that induce immunity to antigens 
of interest expressed from transgenes. Numerous vector-based vaccine candidates have been tested over the last 
decades, targeting a wide range of cancers or infectious diseases1–5. Modified vaccinia virus Ankara (MVA), a 
member of the Orthopoxvirus genus, is a promising vaccine vector derived from the vaccinia virus (VACV) strain 
chorioallantois vaccinia virus Ankara through extensive serial passaging in chicken embryo fibroblasts (CEF). 
This serial passaging resulted in the loss of approximately 15% of the parental genome at so-called ‘deletion 
sites’6,7, allowing for easy generation of recombinant (r)MVA by insertion of one or multiple genes encoding 
antigens of interest into the MVA genome. Furthermore, MVA has lost the ability to replicate in most mammalian 
cell types, leading to an excellent safety record in humans and even safe administration to immunocompromised 
subjects8–11. Since MVA is a replication-deficient vector, it infects cells and drives endogenous expression of anti-
gens under the control of a VACV promotor, resulting in efficient antigen presentation and subsequent induction 
of antigen-specific B and T cell responses3,4,12.
There is considerable interest in the development of novel influenza vaccines that induce broadly protective or 
‘universal’ immunity against different subtypes of influenza A viruses. Accumulation of mutations in the surface 
proteins of seasonal influenza viruses (antigenic drift) and the occasional zoonotic introduction of novel influ-
enza viruses into the human population (antigenic shift) complicate the timely production of ‘classical’ influenza 
vaccines that antigenically match seasonal or pandemic viruses13–17. Furthermore, in case of a pandemic outbreak 
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caused by a newly emerging influenza virus, novel technology is required to rapidly produce large batches of 
vaccines. rMVA vaccines expressing one or multiple influenza virus antigens could potentially fulfill both of these 
needs. Currently, rMVA-based vaccines expressing various wild-type and modified influenza virus antigens are 
evaluated in animal models and clinical trials and have shown promising results3–5.
A potential drawback for the use of orthopoxvirus-based vaccines is that a proportion of the adult human pop-
ulation has immunity against the vaccine vector due to smallpox vaccination campaigns that were conducted until 
the mid 1970s and ultimately led to the eradication of smallpox18. In general, orthopoxvirus-specific immunity 
induced by smallpox vaccination is long-lived with slowly declining T cell responses (half-life of 8–15 years) and 
antibody responses that are maintained up to 75 years after vaccination19. In addition to orthopoxvirus-specific 
immunity induced by the historic use of smallpox vaccines, efficient induction of immunity by rMVA-based vac-
cines often requires repeated administration, which induces immunity not only to the antigen of interest but also 
against the vaccine vector20. There is considerable concern for interference of orthopoxvirus-specific pre-existing 
immunity with subsequent rMVA-based vaccinations, resulting in reduced vaccine immunogenicity and efficacy.
Previously, pre-existing vaccine vector-specific immunity was shown to interfere with VACV-21, fowlpox virus-22  
and adenovirus-based vaccines23,24. In contrast to MVA, these vector-based vaccines are replication-competent in 
their respective hosts and therefore potentially more sensitive to pre-existing vaccine vector-specific immunity. 
Thus far, evidence for interference of pre-existing orthopoxvirus-specific immunity with rMVA vaccination is 
ambiguous. Some studies in mice and macaques showed that pre-existing immunity induced by either VACV 
or MVA had a negative effect on the induction of antigen-specific humoral and/or cellular immune responses 
by rMVA-based vaccines. However, despite the observed negative effects, pre-existing orthopoxvirus-specific 
immunity was not considered to interfere with rMVA-based vaccination25–28. Furthermore, results obtained in 
humans are also contradictory: orthopoxvirus-specific immunity was boosted by multiple rMVA vaccinations 
and was shown to have a negative effect on the magnitude of the antigen-specific humoral and cellular immune 
response. However, in all cases individuals responded to vaccination by either initial induction or boosting of 
antigen-specific immunity20,29. This indicates that rMVA-based vaccines remain immunogenic, even in the 
presence of vector-specific pre-existing immunity. Thus, despite the fact that claims of potential interference by 
pre-existing vector immunity on immunogenicity of rMVA-based vaccines are made in the literature, the topic 
has not been addressed sufficiently and studies have led to contradictory results.
In this study, we addressed the effect of pre-existing immunity to MVA, VACV or influenza virus on the per-
formance of rMVA-based influenza vaccines by evaluating induction of immune responses and the protective 
capacity from a lethal challenge with an influenza virus. Mice were primed with either wild-type (wt)MVA – to 
mimic a scenario of multiple exposures to MVA, for example in a repeated vaccination regimen – or VACV, 
representing people who have been vaccinated against smallpox. Furthermore, (cross-)neutralizing activity of 
MVA- or VACV-specific antibodies against rMVA-based vaccines was assessed using mouse and human sera. 
Importantly, the protective capacity of an rMVA vaccine expressing a hemagglutinin (HA) gene homologous to 
the H5N1 challenge virus was not hampered by the presence of pre-existing immunity to MVA, VACV or influ-
enza virus. However, pre-existing orthopoxvirus-specific immunity interfered with induction of antigen-specific 
antibody responses under specific conditions and had a detrimental effect on the induction of antigen-specific T 
cell responses.
Results
VACV and H1N1pdm09 virus dose-finding. Sub-lethal doses of VACV and pandemic influenza virus 
(H1N1pdm09) were determined in dose-finding experiments in C57BL/6 mice. Inoculation of mice with 104–107 
plaque forming units (PFU) VACV-Elstree by tail scarification led to weight loss (Fig. S1A), concurrent with the 
appearance of blisters at the site of inoculation in all mice (Fig. S1B). Similar levels of VACV-specific antibody 
responses were detected in all groups two weeks after inoculation (Fig. S1c). In addition, VACV- and MVA-
specific CD4+ and CD8+ T cell responses were detected with a trend of stronger T cell responses at increasing 
infectious doses (Fig. S1D,E). A dose of 107 PFU VACV was considered the optimal sub-lethal priming dose for 
subsequent experiments.
In contrast to VACV, intranasal (IN) inoculation of mice with incrementing doses of H1N1pdm09 virus resulted 
in severe weight loss (Fig. S2A). Mortality was observed in mice inoculated with 105 and 106 tissue-culture infectious 
dose −50 (TCID50) of H1N1pdm09 virus (Fig. S2B). Optimal induction of hemagglutination inhibition (HI) anti-
body responses (Fig. S2C) and T cell responses (Fig. S2D) without mortality was observed after inoculation with 104 
TCID50, which was therefore considered the optimal dose for subsequent sub-lethal priming infections.
Induction of pre-existing orthopoxvirus-specific and influenza virus-specific immunity. According 
to the indicated priming regimens (Table 1, week 0 and/or 4) orthopoxvirus-specific or H1N1pdm09 influ-
enza virus-specific immunity was induced. Four weeks after the last priming inoculation (week 8), induction of 
orthopoxvirus- or influenza virus-specific immunity was assessed by measuring serum antibody responses by pro-
tein array (PA) and ELISA. Priming with wtMVA or H1N1pdm09 influenza virus induced homologous antibody 
responses measured by PA (Fig. 1A). Serum antibodies reactive with wtMVA could not be detected in VACV-primed 
mice in this assay. Therefore, induction of VACV-specific antibodies by VACV priming was confirmed by ELISA 
(Fig. 1B). Notably, orthopoxvirus- or influenza virus-specific antibody responses were not detected in unprimed 
mice (Fig. 1A,B). In addition to detection of serum antibodies, H1N1pdm09 virus infection was confirmed by mon-
itoring body weight of mice two weeks post-priming (Table 1, subgroup d). H1N1pdm09-virus inoculated mice lost 
body weight up to 7 days post-inoculation (dpi) and had regained their original weight at 11 dpi (Fig. 1C). In sum-
mary, priming with wtMVA, VACV or H1N1pdm09 was successful and induced detectable pre-existing immunity 
against the respective viruses in C57BL/6 mice.
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Pre-existing orthopoxvirus-specific immunity had limited effect on induction of antigen-specific 
antibody responses by rMVA. To determine the effect of pre-existing immunity on rMVA vaccine immuno-
genicity, unprimed and primed mice were vaccinated with rMVA expressing influenza virus nucleoprotein (NP) or 
HA (Table 1). Serum antibody responses against wtMVA and various HA1 subunits (HA from H1N1pdm09, H3N2 
isolate from 2003 and 2011, and a selection of H5Nx viruses) after a single rMVA vaccination were determined by PA. 
As expected, rMVA vaccination consistently boosted the MVA-specific antibody response in mice primed with wtMVA 
or VACV (Fig. 2A, compare wtMVA response of wtMVA-/VACV-primed mice with unprimed/H1N1pdm09 primed 
mice in all groups). Furthermore, boosting of H1N1pdm09-specific antibodies was observed in mice primed with 
H1N1pdm09 virus and subsequently vaccinated with rMVA-H1 (Fig. 2A, group 3 and 7).
Induction of serum antibody responses against the corresponding antigen (H1pdm09 for rMVA-H1 and 
H3 [2003] for rMVA-H3 vaccination), was not hampered by either orthopoxvirus- or influenza virus-specific 
pre-existing immunity (Fig. 2A). Antibodies against the heterologous H3 (2011) were not detected after a 
single vaccination with rMVA-H3. In contrast, a single rMVA-H5 vaccination led to induction of antibody 
responses to the homologous H5 antigen, as well as heterologous H5 antigens. In wtMVA-primed mice, lower 
antibody titers against the HA1 of all tested H5 clades, including the homologous A/Vietnam/1194/04 (H5N1, 
clade 1), was observed compared to unprimed, VACV- or H1N1pdm09-virus primed mice. This effect was 
particularly detected when a lower dose of rMVA-H5 (107 PFU, Table 1, group 6 at week 12) was used for 
the initial vaccination and to a lesser extent with the use of a higher vaccine dose (108 PFU, Table 1, group 5 
at week 16) (Fig. 2A,B). These results were confirmed by HI assay, which is a good proxy for influenza virus 
neutralization. Corresponding to the PA data, MVA-specific pre-existing immunity negatively affected the HI 
antibody response to influenza virus A/Vietnam/1194/04 after a single rMVA-H5 vaccination, especially when 
a low dose was used (Fig. 2C).
Group
Week 0 Week 4 Week 8 Week 12 Week 16
Prime 1 Prime 2 Vaccination 1 Vaccination 2 Challenge
1
a) — a) —
rMVA-NP rMVA-NP X
b) wtMVA b) wtMVA
c) — c) VACV
d) — d) H1N1pdm09
2
a) — a) —
rMVA-H5 rMVA-H5 X
b) wtMVA b) wtMVA
c) — c) VACV
d) — d) H1N1pdm09
3
a) — a) —
rMVA-H1 rMVA-H1 H5N1
b) wtMVA b) wtMVA
c) — c) VACV
d) — d) H1N1pdm09
4
a) — a) —
rMVA-H3 rMVA-H3 H5N1
b) wtMVA b) wtMVA
c) — c) VACV
d) — d) H1N1pdm09
5
a) — a) —
PBS rMVA-H5 H5N1
b) wtMVA b) wtMVA
c) — c) VACV
d) — d) H1N1pdm09
6
a) — a) —
rMVA-H5* rMVA-H5 H5N1
b) wtMVA b) wtMVA
c) — c) VACV
d) — d) H1N1pdm09
7
a) — a) —
rMVA-H1 rMVA-H5 H5N1
b) wtMVA b) wtMVA
c) — c) VACV
d) — d) H1N1pdm09
Table 1. Experimental design. C57BL/6 mice (n = 6 per subgroup) were unprimed or primed with 108 PFU 
wtMVA (two primings, subgroups b), 107 PFU VACV (one priming, subgroups c) or 104 TCID50 H1N1pdm09 
(one priming, subgroups d). At week 8 and 12, mice were vaccinated with 108 PFU of the indicated rMVA-based 
vaccine expressing influenza virus nucleoprotein (NP) or HA. Groups 1 and 2 were euthanized at week 13 
and 14, respectively, to assess the effect of priming on induction of antigen-specific T cells by vaccination. The 
remainder of the mice was challenged with a lethal dose of 103 TCID50 A/Vietnam/1194/04 (H5N1) influenza 
virus at week 16. *Mice were vaccinated with 107 PFU rMVA-H5.
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A second vaccination with rMVA (Table 1, week 16) boosted serum antibody responses to wtMVA and influ-
enza viruses of interest. Similar to antibody responses induced by a single vaccination, antibody responses against 
the corresponding antigen after two vaccinations with rMVA-H1 or rMVA-H3 were not affected by pre-existing 
immunity (Fig. 3A,B, group 3–4). The second vaccination with rMVA-H3 induced cross-reactive antibody 
responses against an antigenically distinct H3 (2011). Notably, this cross-reactive response was detected in all 
subgroups, but was lower in mice with MVA-specific pre-existing immunity (Fig. 3A,B). Furthermore, in con-
trast to the antibody response after a single rMVA-H5 vaccination, the response after two rMVA-H5 vaccinations 
(Table 1, group 6) or an rMVA-H1 vaccination followed by 108 PFU rMVA-H5 (Table 1, group 7) detected by 
either PA or HI was not affected by pre-existing immunity to the vector (Fig. 3A and C). Interestingly, recurrent 
vaccination with rMVA expressing different antigens (rMVA-H1 and rMVA-H5) still lead to efficient induction 
of antibody responses against both HAs. In conclusion, an effect of pre-existing MVA-specific, but not VACV- or 
influenza virus-specific, immunity on induction of humoral responses by rMVA vaccination was observed under 
specific conditions.
Induction of antigen-specific T cell responses by rMVA is prevented by pre-existing orthopoxvirus- 
specific immunity. To determine the effect of pre-existing immunity on rMVA-induced antigen-specific T 
cell responses, splenocytes were obtained from unprimed and primed mice one or two weeks after the second 
rMVA-NP or rMVA-H5 vaccination, respectively (Table 1, group 1–2). Antigen-specific CD8+ T cell responses 
were determined by measuring the number of interferon (IFN)-γ producing splenocytes after stimulation with 
Figure 1. Induction of orthopoxvirus-specific or influenza virus-specific immunity by priming. (A) Sera from 
individual mice obtained 4 weeks after the last priming (week 8) were assessed by PA for presence of wtMVA- or 
H1N1pdm09-specific antibodies. MVA-specific antibodies were detected with a wtMVA-infected cell lysate, 
mock-infected baby hamster kidney (BHK)-21 cell lysate was included as negative control. Each horizontal 
line represents an individual animal. Antigens (x-axis) and priming groups (y-axis) are indicated. Scale shows 
2-log transformed titers. (B) VACV-specific serum antibody responses were determined by ELISA using VACV-
infected HeLa cell lysate. The background signal on mock-infected cell lysate was subtracted. Individual sera 
from VACV-primed mice were used where possible. Serum from unprimed, wtMVA-primed or H1N1pdm09-
primed mice was pooled due to limited serum availability. Mean per priming group is indicated. Statistically 
significant differences were determined using a one-way ANOVA with multiple comparisons. ****p < 0.0001. 
(C) Mean body weight per group (n = 6, group 7 n = 5) after IN inoculation with 104 TCID50 H1N1pdm09. No 
statistically significant differences between the groups were detected with a repeated measures ANOVA model.
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synthetic peptide NP366–374, an immunodominant CD8+ T cell epitope. Furthermore, the H5-specific CD4+ T 
cell response was determined after stimulation of splenocytes with full-length HA protein from H5N1 influenza 
viruses A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1).
rMVA-NP vaccination efficiently induced antigen-specific CD8+ T cell responses in unprimed and 
H1N1pdm09-primed mice but failed to induce NP-specific CD8+ T cells in mice with orthopoxvirus-specific 
pre-existing immunity, induced by either wtMVA or VACV priming (Fig. 4A). Similar observations were made in 
animals vaccinated with rMVA-H5: unprimed and H1N1pdm09 primed animals developed HA-specific CD4+ 
T cell responses against both the homologous (A/Vietnam/1194/04) and heterologous HA (A/Indonesia/5/05), 
but pre-existing orthopoxvirus-specific immunity had a detrimental effect on the induction of H5-specific CD4+ 
T cell responses (Fig. 4B).
Pre-existing orthopoxvirus-specific immunity impaired the protective efficacy of rMVA-based 
vaccines against challenge with a heterologous but not homologous virus. Four weeks after the 
final vaccination, rMVA-H1, rMVA-H3 and rMVA-H5 vaccinated mice were challenged with a lethal dose of 
influenza virus H5N1 (A/Vietnam/1194/04) in order to determine the effect of pre-existing immunity on the pro-
tective capacity of rMVA-based influenza vaccines (Table 1, group 3–7). As expected, rMVA-H1 and rMVA-H3 
vaccination did not fully protect against an H5N1 influenza virus challenge, which was reflected by loss of body 
Figure 2. Effect of pre-existing immunity on induction of serum antibody responses by a single rMVA 
vaccination. (A–B) Serum antibody responses against wtMVA and HA1 from H1N1pdm09, 2003 H3N2, 
2011 H3N2 or H5 influenza viruses from the indicated clades were determined using PA 4 weeks after the 
first vaccination (group 3, 4, 6 & 7 week 12, group 5 week 16). Mock-infected BHK-21 cell lysates were used 
as negative control for the wtMVA-infected cell lysates. Each horizontal line represents an individual animal 
grouped according to the vaccination group (rMVA-H1, rMVA-H3 or rMVA-H5) and priming subgroup 
(unprimed, wtMVA-primed, VACV-primed or H1N1pdm09-primed) indicated on the y-axis. Each vertical 
bar represents a different antigen (indicated on the x-axis). Scale represents 2-log titers as determined by PA, 
darker colors indicate higher antibody titers. (B) PA titers against H5 from A/Vietnam/1194/04 (clade 1) four 
weeks after rMVA-H5 vaccination with a high dose (108 PFU, group 5, week 16) or a low dose (107 PFU, group 
6, week 12). Mean per priming group is indicated. Statistically significant differences were determined using a 
one-way ANOVA with multiple comparisons. *p = 0.0257, **p < 0.0017. (C) HI titers against influenza virus 
A/Vietnam/1194/04 were determined for each individual animal four weeks after rMVA-H5 vaccination with a 
high dose (108 PFU, group 5, week 16) or a low dose (107 PFU, group 6, week 12). Mean is indicated. Statistically 
significant differences were determined using a Kruskal-Wallis test. *p = 0.0401.
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weight, lower survival rates and high viral loads in the lungs (Fig. 5). However, a limited level of cross-protection 
was observed after rMVA-H1 or rMVA-H3 vaccination in unprimed and H1N1pdm09-primed animals, which 
was not observed in mice primed with VACV or wtMVA (Fig. 5). Notably, pre-existing orthopoxvirus-specific or 
influenza virus-specific immunity did not interfere with the protective capacity of rMVA vaccines expressing the 
homologous HA gene of the H5N1 challenge virus since all mice that received at least one rMVA-H5 vaccination 
were fully protected from lethal H5N1 challenge (Figs 5 and S3).
Pre-existing MVA-specific, but not VACV-specific, antibodies have MVA-neutralizing capacities. 
Whether antibodies induced by single or multiple MVA or VACV exposures have the capacity to recognize and 
neutralize MVA was investigated in vitro by ELISA and a virus neutralization assay. Mice that received a single 
exposure to either MVA or VACV did not induce any detectable MVA-specific serum antibody responses. In 
contrast, in mice that were exposed to MVA at least twice or once to VACV followed by at least one rMVA expo-
sure, MVA-specific antibodies were detected. Notably, the MVA-specific antibody response was not boosted in 
response to additional exposures after the third MVA exposure (Fig. 6A). Similar observations were made in a 
VACV-specific ELISA, where at least two vaccinations with MVA or once with VACV followed by MVA led to 
detectable VACV-reactive antibodies (Fig. 6B). A booster effect of rMVA-based vaccinations after VACV priming 
was observed in both MVA- and VACV-specific antibody responses (Fig. 6A,B). Only sera obtained from mice 
exposed to MVA, but not from mice exposed exclusively to VACV, were capable of neutralizing MVA in vitro 
(Fig. 6C).
Figure 3. Effect of pre-existing immunity on induction of serum antibody responses after two rMVA 
vaccinations. (A–B) Serum antibody responses against wtMVA and HA1 from H1N1pdm09, 2003 H3N2, 2011 
H3N2 or H5 influenza viruses from the indicated clades were determined using protein array 4 weeks after the 
second vaccination (week 16). Each horizontal line represents an individual animal grouped according to the 
vaccination group (2x rMVA-H1, 2x rMVA-H3, 2x rMVA-H5 or rMVA-H1 followed by rMVA-H5) and priming 
subgroup (unprimed, wtMVA-primed, VACV-primed or H1N1pdm09-primed) indicated on the y-axis. Each 
vertical bar represents a different antigen (indicated on the x-axis). Scale represents the 2-log as determined by 
protein array, darker colors indicate higher antibody titers. (B) Protein array titers for each individual animal 
against an antigenically similar H3 from 2003 or distinct H3 from 2011 four weeks after the second rMVA-H3 
vaccination (group 4). Mean per priming group is indicated. Statistically significant differences were determined 
using a one-way ANOVA with multiple comparisons. **p < 0.0086, ***p = 0.0003. (C) HI titers against 
influenza virus A/Vietnam/1194/04 were determined for each individual animal four weeks after the second 
vaccination with rMVA. Mean per priming group is indicated.
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Sera from humans shortly following MVA vaccination, but not 40 years after smallpox vacci-
nation, are capable of neutralizing MVA. Next, the presence of orthopoxvirus-specific antibodies and 
their neutralizing capacity was assessed using serum obtained from humans vaccinated with either VACV ( ± 40 
years post-vaccination) or rMVA (4 weeks after the third vaccination20). MVA-specific antibody responses were 
detected four weeks after vaccination in individuals that received multiple vaccinations with 108 PFU rMVA-H520 
(Fig. 7A). Furthermore, sera from VACV-vaccinated individuals (born between 1970–1971) and unvaccinated 
controls (born between 1976–1978) were probed for the presence of VACV-specific antibodies30. Almost four 
decades after vaccination, VACV-specific antibodies were still detected in VACV-vaccinated individuals, but 
not in the controls that were born 2–4 years after the smallpox vaccination campaign was terminated (Fig. 7B). 
Notably, sera obtained from rMVA vaccinated donors neutralized MVA efficiently in vitro, whereas sera obtained 
from VACV-vaccinated individuals were not capable of neutralizing an MVA infection (Fig. 7C). Although this 
is of course potentially due to waning of VACV-specific antibodies and does not necessarily reflect absence of 
cross-reactivity, this reflects the physiological situation at this time.
Discussion
Although it has been frequently suggested that pre-existing immunity to orthopoxviruses can interfere with 
the immunogenicity and efficacy of rMVA-based vaccines, the issue has not been addressed sufficiently in a 
well-controlled fashion. In this study, we investigated the performance of rMVA-based influenza vaccines in 
the presence or absence of pre-existing immunity to orthopoxviruses or influenza virus in mice and evaluated 
orthopoxvirus-specific immune responses after MVA or VACV vaccination in humans.
Induction of orthopoxvirus-specific antibodies upon priming mice with wtMVA or VACV was confirmed by 
PA and ELISA using wtMVA- or VACV-infected cell-lysates as antigens. Interestingly, VACV-specific antibod-
ies did not cross-react with MVA in our PA assay, whereas MVA-specific antibodies clearly cross-reacted with 
VACV, as demonstrated by ELISA. These results are in accordance with a previous study31 and similar results were 
obtained with human sera, where VACV-specific antibody responses cross-reacted with MVA only to a limited 
extent. In our study, the differential response can be explained by the fact that wtMVA-primed mice received a 
booster immunization inducing a MVA-specific recall response opposed to induction of a primary responses 
in the VACV-primed mice. Indeed, we observed that a single vaccination with rMVA expressing H1, H3 or H5 
in unprimed mice did not induce detectable levels of MVA-specific antibodies, whereas rMVA vaccination of 
VACV-primed mice led to a boosting of MVA-specific antibodies. This corresponds to data obtained in humans, 
which show that MVA-specific antibodies were boosted upon MVA vaccination of either smallpox or rMVA 
vaccinated individuals20,31.
Pre-existing orthopoxvirus-specific immunity in mice affected humoral immune responses induced by rMVA 
influenza vaccines to a limited extent. Effects were exclusively observed in wtMVA-primed mice and only under 
‘suboptimal’ conditions. When a lower rMVA-H5 vaccine dose was used, wtMVA-primed mice had reduced 
antibody titers to all tested H5 clades compared to the other priming groups. The reduced H5-specific antibody 
response observed in mice with MVA-specific pre-existing immunity was overcome by a second immunization 
with 108 PFU of rMVA-H5, as was previously reported27. Furthermore, in wtMVA-primed mice the response 
to an antigenically distinct H3N2 virus was significantly lower after two rMVA-H3 vaccinations compared to 
unprimed animals. However, pre-existing immunity had no effect on the magnitude of the antibody response 
to a corresponding H3 antigen induced by one or two rMVA-H3 vaccinations. Importantly, negative effects on 
the induction of antigen-specific antibody responses induced by rMVA were exclusively observed after wtMVA 
priming. VACV-specific pre-existing immunity never had any effect on the antigen-specific antibody response.
Figure 4. Pre-existing orthopoxvirus-specific immunity inhibits rMVA-induced antigen-specific T cell 
responses. (A) Splenocytes collected 1 week after the second rMVA-NP vaccination were unstimulated or 
stimulated with NP366–374 synthetic peptide. The number of IFN-γ producing CD3+CD8+ splenocytes was 
measured. (B) Splenocytes collected two weeks after the second rMVA-H5 vaccination were unstimulated or 
stimulated with purified HA protein from H5N1 influenza virus A/Vietnam/1194/04 or A/Indonesia/5/05. The 
number of IFN-γ producing CD3+CD4+ splenocytes was measured. Mean of each priming group is indicated. 
Statically significant differences per simulant were determined using a Kruskal-Wallis test. *p < 0.0478, 
**p < 0.0076.
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In addition to antibody responses, the induction of antigen-specific T cell responses after rMVA vaccination 
in the absence or presence of pre-existing immunity was assessed. Virus-specific T cells contribute significantly 
to protective immunity against virus infections and can reduce duration and severity of disease32–34. Induction of 
T cells to influenza virus by vaccines is particularly attractive, since these mainly recognize epitopes in conserved 
internal proteins and can therefore afford cross-protection against various influenza viruses of different subtypes 
(heterosubtypic immunity)35–38. Our results indicated that induction of influenza virus-specific T cell responses 
was severely hampered by presence of MVA- or VACV-specific pre-existing immunity in mice. These findings are 
in concordance with previous studies that examined the immunogenicity of rMVA expressing human immuno-
deficiency virus (HIV) antigens in both mice39 and macaques28,40 in the presence of pre-existing vector-specific 
immunity. In contrast, a recent clinical trial reported efficient induction of cytomegalovirus (CMV)-specific T 
cell responses with rMVA in VACV-vaccinated individuals. The authors claimed that pre-existing VACV-specific 
immunity did not affect immunogenicity of rMVA, however, only a limited number of study subjects with 
pre-existing immunity was studied and their orthopoxvirus immune status was solely defined by date of birth and 
not confirmed with immunological assays41. Furthermore, rMVA expressing NP and matrix 1 (M1) genes from 
influenza virus has been shown to induce T cell responses in humans42,43, even in the elderly that potentially have 
Figure 5. Pre-existing immunity does not impair protective capacity of rMVA-H5 vaccination. Four weeks 
after the last rMVA vaccination, mice were challenged with a lethal dose H5N1 influenza virus. (A) Body weight 
over time for each of the priming groups for group 3 (two rMVA-H1 vaccinations), group 4 (two rMVA-H3 
vaccinations) and group 6 (two rMVA-H5 vaccinations). Mean and standard deviation (SD) per priming group 
are shown. (B) Viral load in the lungs shown as TCID50 per gram lung for each individual animal for group 3, 
group 4 and group 6. Mean of each priming group is shown. Statistically significant differences were determined 
using a Kruskal-Wallis test. *p = 0.0152, **p < 0.0065. (C) Survival after lethal H5N1 influenza virus challenge. 
Mice were euthanized at >25% body weight loss. The absolute number (#; live mice/total mice) and the 
percentage (%) of live animals at seven days post-challenge have been indicated.
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orthopoxvirus-specific immunity44. Although this suggests that T cell responses can be induced in humans with 
VACV-specific immunity, the immune status of study subjects was not verified in these studies and appropriate 
control groups were lacking.
Pre-existing orthopoxvirus- or influenza virus-specific immunity did not affect survival of rMVA-H5 vaccinated 
mice after a lethal H5N1 influenza virus challenge. Protection was most likely mediated by antigen-specific neutralizing 
antibodies, which have been shown to be the main correlate of protection induced by this rMVA-H5 vaccine20,45–48, and 
were unaffected by the presence of pre-existing immunity at week 16. In contrast, mice that were vaccinated with either 
Figure 6. MVA-specific antibodies showed neutralizing capacity. MVA and VACV-specific antibody responses 
were determined in sera obtained four weeks post-priming (week 8) or post-vaccination (week 12&16).  
(A) MVA-specific serum antibody responses were determined using wtMVA-infected BHK-21 cell lysates on 
PA. The mean and SD are indicated. Statistical differences were determined relative to the ‘0 × MVA’ sample 
using a Kruskal-Wallis test. ****p < 0.0001. (B) Serum antibody responses against VACV were measured by 
ELISA using VACV-infected HeLa cell lysate. The background signal on mock-infected HeLa cell lysates was 
subtracted. Due to limited serum availability serum was pooled (n = 3–6) per subgroup. The mean of n = 2–17 
pools is shown, except for ‘3 × MVA’ which shows data from a single pool. (C) Serum antibody responses in 
group 5 (one vaccination with rMVA-H5) and group 6 (two vaccinations with rMVA-H5) were examined for 
wtMVA neutralizing capacity by a plaque reduction assay on CEF. Due to limited serum availability serum 
was pooled (n = 2–5) per subgroup. The mean of n = 2 pools is shown, except for ‘3 × MVA’ and ‘1 × VACV, 
0 × MVA’ which show data from a single pool.
Figure 7. Human rMVA-based, but not VACV, induced MVA-specific neutralizing antibody responses.  
(A,B) Serum antibody responses against MVA (A) and VACV (B) were measured by ELISA using infected 
BHK-21 or HeLa cell lysates, respectively. The background of the respective mock-infected cell lysate was 
subtracted. (C) Neutralizing capacity of orthopoxvirus-specific antibodies was determined by a plaque 
reduction assay on CEF using rMVA-GFP. The data shown are representative of three independent experiments. 
The mean per group is indicated. Statistical significant differences were determined using a Wilcoxon matched-
pairs signed rank test (rMVA vaccination samples) or Mann-Whitney test (VACV vaccination samples). 
*p < 0.0312. **p = 0.0022.
www.nature.com/scientificreports/
1 0SCIENTIfIC RepoRts |  (2018) 8:6474  | DOI:10.1038/s41598-018-24820-2
rMVA-H1 or rMVA-H3 were partially protected from lethal H5N1 influenza virus challenge. A limited level of pro-
tection against H5N1 influenza virus infection was observed in unprimed or H1N1pdm09-primed mice, most likely 
mediated by cross-reactive antibody or T cell responses against influenza virus induced by priming and/or vaccination. 
Notably, mice with pre-existing orthopoxvirus-specific immunity had higher viral loads in the lungs and more severe 
weight loss compared to unprimed or H1N1pdm09 primed mice. In accordance with the described immunogenicity 
results, we hypothesize that orthopoxvirus-specific pre-existing immunity prevented the induction of antibody and/or 
T cell responses by rMVA-H1 or rMVA-H3 vaccination that are cross-reactive with H5.
It has been shown previously that VACV- or MVA-based vaccination efficiently induces both orthopoxvirus- 
specific antibodies and T cell responses19,20,29,49–52 (reviewed in53). Hypothetically, vector-specific antibodies 
induced by previous immunizations could capture and neutralize rMVA virus particles upon (re-)vaccina-
tion, but non-neutralizing antibodies or orthopoxvirus-specific T cells could also play a role in interference. 
Interestingly, VACV-induced pre-existing immunity only interfered with induction of antigen-specific T cell 
responses but not antibody responses whereas MVA-induced pre-existing immunity could interfere with both. 
Since we have demonstrated that VACV-specific antibodies cannot cross-neutralize MVA in vitro, we hypothesize 
that interference of MVA-induced pre-existing immunity with induction of antigen-specific antibody responses 
is mediated by vector-specific antibodies. Similar results were obtained in humans, where VACV-induced anti-
bodies could not neutralize MVA in vitro and only MVA-induced antibodies had MVA-neutralizing capacity. 
Follow-up adoptive transfers studies should be performed to identify the exact mechanism of interference of 
orthopoxvirus-specific immune responses with performance of MVA-based vaccinations.
It is important to note that our study in mice reflects a “worst-case scenario”, since a time interval of only four 
weeks between induction of pre-existing immunity and initial vaccination with rMVA was maintained, not allow-
ing for waning of orthopoxvirus-specific immunity. This does not accurately reflect the human situation, where 
smallpox vaccination was discontinued in the mid 1970s18. Even though VACV-specific antibody responses were 
still detected in the serum of vaccinated individuals by ELISA, these antibodies did not have MVA-neutralizing 
capacity in vitro. However, the timing used in this study does reflect the ‘standard’ interval used in rMVA vaccina-
tion regimens with multiple vaccinations, in which four-week intervals are frequently observed11,20,41. Our results 
show that repeated rMVA vaccination of humans does induce MVA-specific antibodies, which have neutralizing 
capacities in vitro and therefore may interfere with the immunogenicity of subsequent vaccinations.
In conclusion, the present study aids our understanding regarding immunogenicity of MVA-based vaccines 
in the presence of orthopoxvirus-specific immunity. Importantly, in mice rMVA is still immunogenic in the 
presence of orthopoxvirus-specific immunity, however, certain scenarios exist where pre-existing immunity can 
interfere with vaccine efficacy. This study represents an initial foundation to evaluate the effect of pre-existing 
immunity in a well-controlled fashion, future studies are warranted to elucidate the mechanisms underlying this 
interference. When using MVA-based vaccines, it is essential to consider the orthopoxvirus immune status of 
vaccine recipients, the interval between vaccinations in case of repeated rMVA-based vaccination, the vaccine 
dose used and the main correlate of protection induced by rMVA-based vaccines to ensure induction of an opti-
mal immune response.
Materials and Methods
Ethics statement. Animal experiments were conducted in strict compliance with European guidelines (EU 
directive on animal testing 2010/63/EU). The animal protocol was approved by an independent animal experi-
mentation ethical review committee (Erasmus MC permit number EUR3277–02). Animal welfare was observed 
on a daily basis, and all invasive animal handling was performed under anaesthesia using 4% isoflurane in oxy-
gen to minimize animal suffering. Human sera pre- and post-rMVA vaccination (three vaccinations at week 0 
and 56 with 108 PFU rMVA-H5, n = 6) were obtained during a randomized, double-blind phase 1/2a study at 
the Erasmus MC, Rotterdam, the Netherlands. The study involved adult volunteers (male/female, between ages 
18–28) who provided informed consent. The study design was reviewed and approved by the Central Committee 
on Research involving Human Subjects in the Netherlands20. Furthermore, serum samples from VACV vacci-
nated (n = 6) and unvaccinated (n = 6) healthy individuals (male/female) were collected during a cross-sectional 
population-based study performed in the Netherlands from February 2006 until June 2007 (PIENTER2 study)30. 
Smallpox vaccination campaigns lasted until September 1974 in the Netherlands. To limit the inevitable age 
bias, sera from individuals born between 1970–1971 and 1976–1978 were selected for the VACV vaccinated and 
unvaccinated group, respectively. The work described here has been carried out in accordance with the code of 
ethics of the world medical association (declaration of Helsinki).
Cell lines. Madin-Darby Canine Kidney (MDCK) cells were cultured in Eagle’s Minimum Essential Medium 
(EMEM, Sartorius Stedim BioWhittaker) supplemented with 10% fetal bovine serum (FBS, Greiner Bio-One), 
20 mM HEPES (Lonza BioWhittaker), 0.1% CHNaO3 (Lonza BioWhittaker), and 100 μg/ml penicillin, 100U/
ml streptomycin and 2mM L-Glutamine (P/S/G, Lonza). CEF were isolated from 11-day-old chicken embryos 
(Drost Loosdrecht BV) and passaged once before use as described previously45. CEF were cultured in Virus 
Production-Serum Free Medium (VP-SFM, Gibco) containing P/S. HeLa cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Lonza) supplemented with 10% FBS, 20 mM HEPES, 0.1% CHNaO3 and 
P/S/G. Baby Hamster Kidney (BHK)-21 cells were cultured in DMEM supplemented with 10% FBS, 20 mM 
HEPES, 0.1% CHNaO3, 0.1 mM non-essential amino acids (NEAA, Lonza) and P/S/G. HeLa cells were cultured 
in DMEM supplemented with 10% FBS, 20 mM HEPES and 0.1% CHNaO3 and P/S/G. All cells were cultured at 
37 °C in a humidified atmosphere with 5% CO2.
Viruses. rMVA expressing the NP gene of influenza virus A/Puerto Rico/8/34 (PR8, rMVA-NP), the HA 
gene of A/Vietnam/1194/04 (rMVA-H5) or A/Netherlands/213/03 (rMVA-H3) under the control of the psynII 
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promotor, rMVA expressing the HA gene of influenza virus A/California/4/2009 (rMVA-H1) under control of 
the PH5 promotor and rMVA expressing GFP under control of the P11 promotor were prepared as described 
previously45,54–56. To generate final vaccine preparations of MVA-F6 (empty vector, wtMVA) or rMVA, the viruses 
were propagated in CEF, purified by ultracentrifugation through 36% sucrose and resuspended in 120 mM NaCl 
10 mM Tris-HCl pH 7.4. rMVA constructs were validated by PCR analysis, sequencing, plaque titration, western 
blot and/or flow cytometry. The VACV strain Elstree was grown in HeLa cells as described above for the rMVA 
constructs on CEF cells. Influenza A viruses A/Netherlands/602/09 (H1N1pdm09) and A/Vietnam/1194/04 
(H5N1) were propagated and titrated (TCID50) in MDCK cells as described previously57.
Mice. Specified pathogen free (SPF) female C57BL/6 mice 6–8 weeks of age (Charles River) were housed at 
biosafety level (BSL-)2 in individual ventilated cage (IVC) units during priming and vaccination (week 0–15). 
During the H5N1 influenza virus challenge, mice were housed in filter-top cages in negatively pressured BSL-3 
isolators (week 16–17). At all times, mice had access to food and water ad libitum.
H1N1pdm09 virus and VACV-Elstree dose-finding. Four groups of mice (10–12 weeks old, n = 6) were 
inoculated with 104, 105, 106 or 107 PFU VACV-Elstree in 10 μl PBS by intradermal (ID) tail scarification with a 
25–29 G needle58 or IN with 103, 104, 105 or 106 TCID50 H1N1pdm09 in 50 μl PBS. Clinical signs, weight loss and 
survival were recorded for 14 days, mice were euthanized 14 dpi or earlier when pre-defined humane endpoint 
criteria were met (>25% body weight loss).
Priming, rMVA vaccination and challenge. Mice (6–8 weeks old) were divided into seven groups (n = 24) 
with four subgroups (n = 6) each (Table 1). Animals were either unprimed (subgroup a) or were primed with 108 PFU 
wtMVA in 100 μl PBS intramuscularly (IM, two immunizations at week 0 and 4, subgroup b), 107 PFU VACV-Elstree 
(week 4, subgroup c) or 104 TCID50 H1N1pdm09 (week 4, subgroup d). VACV-Elstree and H1N1pdm09 were admin-
istered as described above at the optimal priming dose determined in the dose-finding experiments mentioned above. 
After priming, mice received one or two IM vaccinations at week 8 and/or 12 with 108 PFU of rMVA-NP, rMVA-H1, 
rMVA-H3 and/or rMVA-H5 in 100 μl PBS. Of note, 107 PFU rMVA-H5 was administered at week 8 to the mice of 
group 6 (Table 1) to establish if pre-existing immunity affects low dose rMVA-HA vaccination and if a boost with a 
high dose could overcome potential negative effects. After vaccination, mice vaccinated with rMVA-NP or rMVA-H5 
were not challenged and were euthanized one (week 13) or two weeks (week 14) after the second vaccination, respec-
tively (Table 1, group 1–2). The remainder of the animals (Table 1, group 3–7) were challenged IN with 103 TCID50 A/
Vietnam/1194/04 (H5N1) influenza virus four weeks after the second vaccination (week 16) and monitored twice daily. 
Mice were euthanized when pre-defined humane endpoint criteria (>25% body weight loss) were reached or at seven 
days post-challenge (week 17). Blood, spleen and/or lung samples were harvested during necropsy. A single mouse in 
the wtMVA-primed subgroup of the 2 × rMVA-H5 challenge group (group 6, subgroup b) had to be euthanized due 
to a wound unrelated to the experiment at week 4. One mouse in the H1N1pmd09-prime group of the 1 × rMVA-H1 
and 1 × rMVA-H5 group (group 7, subgroup d) had to be euthanized 10 days after priming because humane endpoint 
criteria were met. These mice were excluded from further analysis. Animal experiments with groups 3 & 7 and 5 & 6 
were performed in parallel but at different stages, groups 1 & 2 and group 4 were performed separately. Analysis of the 
samples was performed collectively for all groups.
Virus isolation from lungs. Directly after necropsy, all lungs were snap frozen and stored at −80 °C for 
processing at a later time point. To perform virus isolations, lungs were thawed, lung weight was recorded and 
lungs were homogenized with a Polytron homogenizer (Kinematica AG) in MDCK infection medium (without 
FBS). Quadruplicate ten-fold serial dilutions of these samples in MDCK infection medium supplemented with 
0.002% TPCK-Trypsin (Lonza) were used to determine the virus titers on MDCK cells as described previously57.
Stimulation and intracellular cytokine staining of splenocytes. During necropsy spleens were col-
lected in Iscove’s Dulbecco’s Medium (IMDM, Lonza) supplemented with 5% FBS and P/S/G for direct preparation 
of single cell suspensions using 100 µm strainers (Falcon). Erythrocytes were removed from single cell suspensions 
by treatment with red blood cell lysis buffer (Roche diagnostics). For intracellular cytokine staining, splenocytes 
were stimulated with 5 µM synthetic peptide (epitope NP366–374: ASNENVEIM [Fig. S2] or ASNEMMETM [Fig. 4]) 
or 1 µg/250,000 cells recombinant HA protein from H5N1 influenza virus A/Vietnam/1203/04 or A/Indonesia/5/05 
(Protein Sciences) in IMDM supplemented with GolgiStop and incubated for 6 h at 37 °C. Mock-treated spleno-
cytes and splenocytes stimulated with 50 ng/ml PMA (Sigma-Aldrich) and 0.5 µg/ml ionomycin (Sigma-Aldrich) 
served as appropriate negative and positive controls. After stimulation, splenocytes were incubated with 
fluorochrome-labeled antibodies to CD3eAPC-Cy7 (BD Pharmingen), CD8bFITC (BD Pharmingen), CD4PerCP (BD 
Pharmingen) and viable cells were identified with Aqua LIVE/DEAD (Invitrogen). Subsequently, cells were fixed 
and permeabilized using BD Cytofix/CytopermTM Plus (BD Biosciences), and incubated with anti-IFN-γPacificBlue 
(Biolegend). Samples were acquired on a FACS Canto II and data was analyzed as described previously55,59 using 
FACS Diva software (BD Biosciences).
Protein Array (PA) assay. Mouse sera collected at week 8 and 16 (Table 1) were used to determine the pres-
ence of antibodies to selected antigens by PA as described previously60,61. In short, recombinant HA1 derived from 
influenza viruses A/California/6/2009 (pH1), A/Wyoming/3/2003 (H3 2003), A/Victoria/361/2011 (H3 2011), A/
Hong Kong/156/97 (H5 clade 0), A/Vietnam/1194/04 (H5 clade 1), A/Cambodia/R045050/2007 (H5 clade 1.1), A/
Indonesia/5/05 (H5 clade 2.1), A/Turkey/15/2006 (H5 clade 2.2), A/Turkey/Germany-MV/R2472/2014 (H5 clade 
2.3.4.4), A/goose/Guiyang/337/2006 (H5 clade 4) and A/chicken/Vietnam/NCVD-016/2008 (H5 clade 7), as well 
as uninfected and wtMVA infected BHK-21 cells lysed in 1% Triton-X100 (Sigma) in PBS supplemented with mini 
cOmplete™ EDTA free protease inhibitor tablet (Roche) were printed onto nitrocellulose slides by asciFlexarraver 
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(Scienion). Sera were incubated on the slides in Blotto Blocking Buffer (Thermo Fisher Scientific Inc.) supplemented 
with 0.1% Surfactant-Amps (Thermo Fisher Scientific Inc.). Subsequently, goat-anti-human IgG labelled with 
AlexaFluor647 (Jackson ImmunoResearch Laboratories Inc.) was used as conjugate and fluorescent signals were 
measured using a Powerscanner (Tecan Group Ltd). The titer of each serum sample was defined as the interpolated 
serum concentration generating the 50% point using a four-parameter logistic nonlinear regression model using R 
(R Statistical Computing, version 3.1.0. Measured titers were corrected for the positive control included on each slide.
Detection of MVA- or VACV-specific antibodies by ELISA. For detection of VACV-specific antibodies, 
HeLa cells were mock-treated or infected with VACV-Elstree at MOI 1 and harvested in 1% Triton-X100 in PBS 
supplemented with mini cOmplete EDTA free protease inhibitor tablet. Similar procedures were used to obtain 
BHK-21 cell lysates mock-treated or infected with wtMVA. Sera used for detection of MVA- or VACV-specific 
antibodies were pre-cleared O/N at 4 °C in a 96-well plate with confluent BHK-21 or HeLa cells, respectively. For 
ELISA, 96-well plates (Corning Costar) were coated overnight at 4 °C with 10–25 µl cell lysate (mock-treated or 
infected) per well in 0.05 M Carbonate/Bicarbonate pH 9.6. Plates coated with cell lysate were washed and all 
plates were blocked for 1 h at room temperature (RT) with blocking buffer consisting of PBS supplemented with 
0.05% Tween-20 (PBST, Merck-solutions) and 2% milk powder (w/v, Campina). Subsequently, a 3-log dilution 
series of serum in blocking buffer was prepared, starting dilution 1:10 or 1:30, and 50 μl was transferred to wells 
of the antigen-coated plates and incubated for 1–1.5 h at RT. Blocking buffer and VACV-positive serum served 
as appropriate negative or positive control, respectively. Plates were washed with PBST and incubated for 1 h at 
RT with HRP-conjugated goat-anti-mouse IgG (DAKO) or goat-anti-human IgG (Southern Biotech). Plates were 
washed with PBST and incubated for 10 min with 50 µl TMB peroxidase substrate (KPL) after which the reaction 
was stopped with 0.5 M H2SO4 (Merck). Absorbance was measured at 450 nm using a Tecan infinite F200. The 
OD450 values at a single dilution in the linear area of the curve were determined and analysed. Due to limited 
amounts of serum, sera were pooled per subgroup (Table 1, n = 3–6). Sera of VACV-primed animals were tested 
individually in VACV ELISA as much as possible, although in some groups a few samples had to be pooled (indi-
cated in figure legends). The OD450 value obtained with mock-infected BHK-21 or HeLa cell lysate was subtracted 
from the OD450 value obtained with the respective infected cell lysate to determine a net OD450 response.
Hemagglutination inhibition (HI) assay. Sera were treated with a receptor-destroying enzyme (cholera 
filtrate) overnight at 37 °C, followed by heat-inactivation for 1 h at 56 °C. HI assay was performed in a 2-fold 
serial dilution in duplicate following a standard protocol using 1% turkey erythrocytes and four HA units of an 
H5N1 reverse genetics influenza virus with HA (without multibasic cleavage site) and NA gene segments of A/
Vietnam/1194/04 and the remaining gene segments of influenza virus A/Puerto Rico/8/34 (6 + 2)62.
Plaque reduction assay. Mouse sera were pooled per subgroup (Table 1, n = 2–5) due to limited serum avail-
ability. Sera were heat-inactivated for 30 min at 56 °C. A 2-log dilution series – starting dilution 1:10 – was prepared 
in CEF culture medium and incubated for 2 h with 200 PFU/well wtMVA (mouse sera) or rMVA-GFP (human sera) 
in a 1:1 ratio at 37 °C. Human serum with antibodies against MVA was used as a positive control. Subsequently, the 
serum-virus mixture was incubated for 2 h at 37 °C on a confluent monolayer of CEF cells in 96-wells culture plates. 
Cells were washed with PBS and incubated for 44–48 h 37 °C. CEF used for serology of mouse samples were fixed 
with acetone/methanol (Sigma-Aldrich). Plates were blocked with 3% FBS in PBS for 1 h. Subsequently, plaques 
were stained with rabbit anti-VACV (Lister strain, Acris) followed by goat-anti-rabbit HRP-conjugate (Jackson 
ImmunoResearch Laboratories Inc.). Samples were developed using True Blue (KPL). The percentage of area cov-
ered by stained plaques was measured using a CTL immunospot reader with CTL biospot software. CEF used for 
serology of human samples were fixed with 2% paraformaldehyde (PFA) for 10 min after which fluorescent plaques 
were detected using a Typhoon™ FLA9500 (GE Healthcare). Plaques were counted using ImageQuant TL Colony 
v8.1 software (GE Healthcare). The MVA-neutralization titer was determined as the reciprocal of the highest dilution 
at which the area covered by plaques was below 50% of the average percentage of the area covered (mouse sera, Fig. 
S4A) or counted spots (human sera, Fig. S4B) in n = 12 wells without any added serum.
Statistical analysis. Longitudinal body weight data after H1N1pdm09 priming was analyzed using a repeated 
measures ANOVA model, with time as within factor. One way ANOVA with multiple comparisons was used to com-
pare the normally distributed (according to the Shapiro-Wilk test) VACV-specific antibody responses after priming 
(week 8), H5-specific PA antibody responses after one vaccination and the 2003/2011 H3-specific PA antibody 
responses in mice. A Kruskal-Wallis test was used to compare the not normally distributed HI titers against A/
Vietnam/1194/04 after a single vaccination, NP- or H5-specific T cell responses and viral lung titers. HI titers below 
the detection limit (titer 40) were set to a titer of 20 (the highest possible titer below 40). Statistical differences in 
the MVA-specific PA response were determined relative to the ‘0 × MVA’ control sample using a Kruskal-Wallis 
test. Furthermore, the ELISA and neutralization titers in human serum samples were compared using a Wilcoxon 
matched-pairs signed rank test (MVA sera) or a Mann-Whitney test (VACV sera). Neutralization titers in the plaque 
reduction assay below the detection limit (10) were set to a titer of 5 (the highest possible titer below 10).
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